CASI Competitors
| CASI Stock | USD 0.92 0.03 3.16% |
CASI Pharmaceuticals vs Lipocine Correlation
Very good diversification
The correlation between CASI Pharmaceuticals and LPCN is -0.32 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding CASI Pharmaceuticals and LPCN in the same portfolio, assuming nothing else is changed.
Moving against CASI Stock
| 0.75 | DSGN | Design Therapeutics | PairCorr |
| 0.67 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.56 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.48 | ENGN | enGene Holdings Common | PairCorr |
| 0.34 | 63E | ONWARD MEDICAL BV | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CASI Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CASI Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between CASI Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of CASI and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of CASI Pharmaceuticals does not affect the price movement of the other competitor.
| 0.85 | -0.26 | 0.74 | -0.87 | GOVX | ||
| 0.85 | -0.1 | 0.64 | -0.73 | BLRX | ||
| -0.26 | -0.1 | 0.2 | 0.4 | THAR | ||
| 0.74 | 0.64 | 0.2 | -0.57 | AIMD | ||
| -0.87 | -0.73 | 0.4 | -0.57 | LPCN | ||
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between CASI Stock performing well and CASI Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze CASI Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 5.33 | (2.41) | 0.00 | (0.83) | 0.00 | 9.38 | 42.89 | |||
| BLRX | 2.59 | (0.27) | 0.00 | (0.19) | 0.00 | 5.20 | 13.04 | |||
| THAR | 5.48 | 0.50 | 0.08 | 0.40 | 5.92 | 11.55 | 40.06 | |||
| AIMD | 4.50 | (0.89) | 0.00 | (0.22) | 0.00 | 12.30 | 38.73 | |||
| LPCN | 5.03 | 2.00 | 0.39 | (14.40) | 3.32 | 15.95 | 33.09 |
Cross Equities Net Income Analysis
Compare CASI Pharmaceuticals and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 36.7 M | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.9 M) | (18.5 M) | (14 M) | (26 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (32.1 M) | (13.2 M) | (20.4 M) | (17.6 M) | (10.2 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| LPCN | (5.2 K) | (5.2 K) | (76.7 K) | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.4 M) | 8.4 K | 7.5 K | 7.9 K |
CASI Pharmaceuticals and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in CASI Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of CASI Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.CASI Pharmaceuticals Competitive Analysis
The better you understand CASI Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, CASI Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across CASI Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
CASI Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of CASI Pharmaceuticals Competition
CASI Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by CASI Pharmaceuticals in relation to its competition. CASI Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of CASI Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact CASI Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to CASI Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your CASI Pharmaceuticals position
In addition to having CASI Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Strategy ETFs Thematic Idea Now
Strategy ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Strategy ETFs theme has 1748 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Strategy ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out CASI Pharmaceuticals Correlation with its peers. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is there potential for Biotechnology market expansion? Will CASI introduce new products? Factors like these will boost the valuation of CASI Pharmaceuticals. Projected growth potential of CASI fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets | Return On Equity |
Investors evaluate CASI Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CASI Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause CASI Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between CASI Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CASI Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CASI Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.